Releases
MRUS
--
0.00%
--
  • All
  • Financials
  • Insiders
More
Webull provides the latest Merus (MRUS) stock and general news. This information may help you make smarter investment decisions.
About MRUS
Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products include, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as well as MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.